HER2-Positive Breast Cancer Market Driven by Therapeutic Advancements
The HER2-Positive Breast Cancer Market encompasses a range of targeted therapeutics designed to inhibit the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in approximately 20–25% of breast cancer cases. Key products include monoclonal antibodies (trastuzumab, pertuzumab), antibody–drug conjugates (ado-trastuzumab emtansine), tyrosine kinase...
0 Yorumlar 0 hisse senetleri 125 Views 0 önizleme